CompanyGraph
OneSource Specialty Pharma Inc.
ONESOURCE · NSE India · India
onesourcecdmo.comFinancials as of FY2026
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $1.84B, above the global median of $1.15B
- PositionCurrent ratio is 0.99×, lower than 95% of its Biotechnology peers (median 5.64×)
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
176.02BINR1.84B · vs all stocks (USD)
Revenue (TTM)
15.43BINR161.26M · vs all stocks (USD)
Profit Margin
-3.15%vs Biotechnology peers
52-Week Change
-18.51%vs all stocks
Market Capitalization
176.02BINR1.84B · vs all stocks (USD)
Enterprise Value
188.36BINR1.97B · vs all stocks (USD)
Forward P/E
20.14xvs Biotechnology peers
Price to Sales (TTM)
11.30xvs Biotechnology peers
Price to Book (MRQ)
3.00xvs Biotechnology peers
Enterprise to Revenue
12.21xvs Biotechnology peers
Enterprise to EBITDA
54.85xvs Biotechnology peers
Gross Margin
68.30%vs Biotechnology peers
Profit Margin
-3.15%vs Biotechnology peers
Operating Margin
11.49%vs Biotechnology peers
Return on Assets (TTM)
-0.90%vs Biotechnology peers
Return on Equity (TTM)
-1.27%vs Biotechnology peers
Revenue (TTM)
15.43BINR161.26M · vs all stocks (USD)
Revenue per Share (TTM)
128.59INRUpdated Aug 22, 2026Quarterly Revenue Growth
37.20%vs Biotechnology peers
Gross Profit (TTM)
10.49BINR109.64M · vs all stocks (USD)
EBITDA (TTM)
3.53BINR36.85M · vs all stocks (USD)
Net Income (TTM)
-486.20MINR-5.08M · vs all stocks (USD)
Operating Cash Flow (TTM)
85.23MINR890.57K · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-738.03MINR-7.71M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00INRUpdated Aug 22, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
14.22BINRFY2026 · Mar 31, 2026Cost of Goods Sold
4.45BINRFY2026 · Mar 31, 2026Gross Profit
9.77BINRFY2026 · Mar 31, 2026Operating Income
251.29MINR2.63M · vs all stocks (USD)
Pre-tax Income
-919.61MINRFY2026 · Mar 31, 2026Income Tax Expense
-181.58MINRFY2026 · Mar 31, 2026Net Income
-738.03MINRFY2026 · Mar 31, 2026EBIT
302.24MINRFY2026 · Mar 31, 2026EBITDA (Income Statement)
3.19BINRFY2026 · Mar 31, 2026Other Operating Expenses
4.30BINRFY2026 · Mar 31, 2026Non-operating Interest Expense
1.22BINRFY2026 · Mar 31, 2026Preferred Stock Dividends
0.00INRFY2026 · Mar 31, 2026Operating Cash Flow
-4.64BINRFY2026 · Mar 31, 2026Cash & Cash Equivalents (End of Period)
383.37MINRFY2026 · Mar 31, 2026Starting Profit (CF Statement)
-919.61MINRFY2026 · Mar 31, 2026Stock-based Compensation
27.10MINRFY2026 · Mar 31, 2026Other Non-cash Items
1.10BINRFY2026 · Mar 31, 2026Change in Accounts Receivable (CF)
-1.90BINRFY2026 · Mar 31, 2026Change in Other Assets/Liabilities
-2.96BINRFY2026 · Mar 31, 2026Purchase of Investments
-128.42MINRFY2026 · Mar 31, 2026Other Investing Activity
869.27MINRFY2026 · Mar 31, 2026Net Investing Cash Flow
740.85MINRFY2026 · Mar 31, 2026Long-term Debt Issuance
5.64BINRFY2026 · Mar 31, 2026Long-term Debt Payments
-2.07BINRFY2026 · Mar 31, 2026Net Short-term Debt Issuance
1.40BINRFY2026 · Mar 31, 2026Net Financing Cash Flow
5.02BINRFY2026 · Mar 31, 2026Shares Outstanding
114.67MSharesUpdated Aug 22, 2026Float Shares
65.71MSharesUpdated Aug 22, 2026% Held by Insiders
35.49%vs all stocks
% Held by Institutions
33.02%vs all stocks
Total Cash (MRQ)
1.03BINR10.77M · vs all stocks (USD)
Total Cash per Share (MRQ)
8.98INRUpdated Aug 22, 2026Total Debt (MRQ)
15.04BINR157.15M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.2579xvs Biotechnology peers
Current Ratio (MRQ)
0.9889xvs Biotechnology peers
Book Value per Share (MRQ)
507.40INRUpdated Aug 22, 2026Total Assets
82.10BINR857.86M · vs all stocks (USD)
Total Current Assets
14.26BINRFY2026 · Mar 31, 2026Total Liabilities
23.79BINRFY2026 · Mar 31, 2026Total Non-current Assets
67.84BINRFY2026 · Mar 31, 2026Total Non-current Liabilities
9.37BINRFY2026 · Mar 31, 2026Total Current Liabilities
14.42BINRFY2026 · Mar 31, 2026Cash & Cash Equivalents
356.76MINRFY2026 · Mar 31, 2026Other Short-term Investments
838.10MINRFY2026 · Mar 31, 2026Accounts Receivable
6.90BINRFY2026 · Mar 31, 2026Inventory
4.39BINRFY2026 · Mar 31, 2026Accounts Payable
3.75BINRFY2026 · Mar 31, 2026Short-term Debt
7.21BINRFY2026 · Mar 31, 2026Other Current Liabilities
2.65BINRFY2026 · Mar 31, 2026Long-term Debt
7.82BINRFY2026 · Mar 31, 2026Other Non-current Liabilities
10.26MINRFY2026 · Mar 31, 2026Common Stock (Book)
114.62MINRFY2026 · Mar 31, 2026Total Shareholders' Equity
58.31BINR609.31M · vs all stocks (USD)
52-Week Low
1.06KINRUpdated Aug 22, 202652-Week High
1.93KINRUpdated Aug 22, 202652-Week Change
-18.51%vs all stocks
50-Day MA
1.62KINRUpdated Aug 22, 2026200-Day MA
1.59KINRUpdated Aug 22, 2026Avg 10-Day Volume
181.69KSharesUpdated Aug 22, 2026Avg 30-Day Volume
272.42KSharesUpdated Aug 22, 2026Diluted EPS (TTM)
-4.11INRUpdated Aug 22, 20262 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Diagnostic
Goodwill-Heavy Equity
Equity looks heavy for the industry, but much of it is goodwill from past acquisitions.
Reads
Where is this company structurally exposed?
Receivables Heavy and Growing
Money owed by customers keeps growing, and is much of its current assets.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Current ratio is 0.99×, lower than 95% of its Biotechnology peers (median 5.64×)Significant
Current ratio: 0.99Industry median: 5.64Industry P5: 1.06Peers compared: 261
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.68Profit Margin: -0.03
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -1.36
Altman Z-Score 4.95: safe zoneNotable
Altman Z-Score: 4.95
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $1.84B, above the global median of $1.15BNotable
Market cap (USD): 1,839,263,153.421Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
Shenzhen Edge Medical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Idorsia Ltd
Tier 1ProductionApproval-Gated PipelineRuleRisk
Shenzhen Chipscreen Biosciences Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Staidson (Beijing) Biopharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Novocure Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Ascletis Pharma Inc.
Tier 1ProductionApproval-Gated PipelineRule
Cohance Lifesciences Limited
Tier 1ProductionApproval-Gated PipelineRule
Mirxes Holding Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hunan Jingfeng Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
D&D Pharmatech Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Companies that share active interpretations — structural patterns currently present in both stocks.
Sagility India Ltd.
2 interpretationsGoodwill-Heavy EquityReceivables Heavy and Growing
Rollins, Inc.
2 interpretationsGoodwill-Heavy EquityReceivables Heavy and Growing
Thomson Reuters Corporation
2 interpretationsGoodwill-Heavy EquityReceivables Heavy and Growing